Newscasting from ACC 2024: AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia
Use of CSL112, a 6 mg infusion of apolipoprotein A-I (ApoA-1), was not associated with a reduction in major adverse cardiovascular events in the AEGIS-II trial, according to data presented at the American College of Cardiology (ACC 2024) Annual Scientific Session.
A phase 3 trial aimed at assessing the effects of cholesterol efflux on cardiovascular risk, results demonstrate use was not associated with a reduction in the primary endpoint at 90 days. Still, investigators called attention to additional analyses suggesting use could provide a reduction in events after the 90-day endpoint, with data indicating an apparent reduction at 6 months and beyond.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
